B-SMART: Hepatitis B Webcast
Hepatitis B virus (HBV) remains a major
Despite the overwhelming success of immunization, in the United States 1.2 million are infected, due in large measure to immigrants from high endemic areas. This series is intended for hepatologists, gastroenterologists, infectious disease physicians, primary care physicians, infectious disease and gastroenterology nurse practitioners, infection control nurses, physician assistants, and others involved with the health care of HBV patients or those at increased risk for acquiring the infection.
Epidemiologic studies suggest that Asian Americans have one of the highest rates of HBV infection. In contrast to the general population, their rate has grown a substantial 72% since 1990, and it is projected to continue to increase. Evidence indicates that socioeconomic and culture factors are the greatest barriers to successful screening, diagnosis, prevention, and treatment of Asian American populations. These barriers include language, income and poverty, education, citizenship issues, and access to health care.
The Cleveland Clinic Center for Continuing Education is delighted to present BSMART: Hepatitis B webcast series. This series will review the natural history, diagnosis, management, and prevention of HBV infection, including methods to overcome the cultural barriers and complications that impede healthcare advancement in immigrant populations.
|Watch Introduction by Dr. Carey|
|Understanding Cultural Barriers|
|Estimated Time: 15 minutes
Release Date: January 15, 2009
|Technical Requirements: Windows Media
Specialties: Gastroenterology, Infectious Disease, Family Practice, Hepatology
- Summarize the epidemiologic and natural history of hepatitis B.
- Translate emerging clinical trial data as it relates to hepatitis B practice guidelines.
- List methods for raising awareness of the importance of HBV prevention through immunization.
- Identify cultural barriers to management of HBV infection in Asian Americans and detail strategies to overcome the barriers.
- Compare and contrast therapeutic profiles for drug classes approved to treat hepatitis B infection, including data on combination therapies.
William D. Carey, MD
Professor of Medicine
Cleveland Clinic Lerner College of Medicine
Department of Gastroenterology Hepatology
Digestive Disease Institute